Replies to post #211396 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

He’s behaving as if he knows at least thumbs up or down from any prior efficacy interim analysis. Why would he talk about crossover and different approaches to proceed in different countries? You don’t do that if you get thumbs up on both endpoints, The question needs to be asked, how many efficacy IAs were performed and what type of info was management allowed to hear?

[exwannabe]

Randomization. Spent some time on this question over at the wolf den.

It is a bit hard to swallow that the error was pure chance. The randomization is not done by flipping a (3 sided) coin for each patient. They use a centralized strategy that balances the trial out.

There are some very naive strategies that would make no effort to keep a trial balanced prior to the end (they are always balanced when over). I modeled the one that I thought would be the worst on this issue, and there was something like a 1% chance this could happen.

But I thought they would have chosen one of several techniques that are well known to avoid this. And Hodag weighed in saying my maive approach would never be used in the real world.

So I am more than a bit skeptical about Les's assertion there is nothing to see on the issue.

[iwasadiver]

Many companies are much clearer about their timeline.

So, who are they and where is your proof? Otherwise you're guilty of the same thing you're accusing Les Goldman of.

Also, the only question I see that could remotely be seen as a dodge is the first one. But I understand the vagueness of it personally.

Please explain why you say the other questions were a "dodge" and what you'd expect based on the reasons he gave to not answer questions too completely? What reasons do you believe are behind their vagary? Just to be dicks?